Efficacy and Safety of Low-dose Ticagrelor

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

3,043

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

December 13, 2018

Study Completion Date

February 13, 2019

Conditions
Coronary Artery Disease
Interventions
DRUG

Ticagrelor

ticagrelor 45 mg twice daily for 5 consecutive days at least.

DRUG

ticagrelor

ticagrelor 90 mg once daily for 5 consecutive days at least.

DRUG

ticagrelor

ticagrelor 90 mg twice daily for 5 consecutive days at least.

DRUG

clopidogrel

clopidogrel 75 mg once daily for 5 consecutive days at least.

Trial Locations (1)

100001

Thromboela-Stogram, Beijing

All Listed Sponsors
collaborator

Beijing Anzhen Hospital

OTHER

collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

collaborator

The Central Hospital of Jia Mu Si City

UNKNOWN

collaborator

First Affiliated Hospital of Kunming Medical University

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

Tianjin Medical University General Hospital

OTHER

collaborator

Weifang People's Hospital

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Shengjing Hospital

OTHER

collaborator

Shaanxi Provincial People's Hospital

OTHER

lead

First Affiliated Hospital of Harbin Medical University

OTHER

NCT03381742 - Efficacy and Safety of Low-dose Ticagrelor | Biotech Hunter | Biotech Hunter